Signal Explorer

Ipo Net Proceeds Disclosure Convertible Notes Conversion Terms Disclosed Change Of Control Redemption Provision Convertible Debt Conversion Successor Agent Appointment Provision Market Price Definition Restrictive Debt Covenants Disclosure Debt Note Interest Terms Disclosed Classified Board Director Election Share Withholding Tax Settlement New York Jurisdiction Clause Ipo Or Capital Raising Completion Nyse Listing Disclosure Amendment Modification Waiver Clause Indemnification Consent Requirement

Net Loss Reported Priority Review Or Pdufa Disclosed Personnel Cost Decrease Disclosure Mrna Drug Platform Checkpoint Inhibitor Program Interim Data Positive Administrative Efficiency Revenue Decline Explanation Inventory Writedown

Combination Therapy Mentioned Near Term Regulatory Decision Clinical Trial Result Lead Asset Progress Indication Expansion

Demand Softening

Revenue Decline Explanation Director Officer Indemnification Provision Financing Activities Cash Flow Disclosure Share Repurchase Activity Disclosed Depreciation Expense Composition Disclosure Net Loss Reported Quarterly Tax Provision Benefit Disclosure Personnel Cost Decrease Disclosure Effective Tax Rate Reconciliation Administrative Efficiency Burn Rate Controlled Liquidity Position Snapshot Disclosed Shares Outstanding Disclosure

Demand Softening

Combination Therapy Mentioned

Classified Board Director Election Board Committee Composition Disclosure Director Continuity Stated Kol Endorsement Employee Director Compensation Waiver

Say On Pay Vote Result Disclosed Auditor Appointment Ratification Classified Board Director Election Equity Plan Board Approval Conditional On Shareholder Vote Adjournment Proposal Voting Requirement

Share Repurchase Activity Disclosed New York Jurisdiction Clause Net Loss Reported Financing Activities Cash Flow Disclosure Change Of Control Definition Revenue Decline Explanation Cash Flow Statement Investing Activities Effective Tax Rate Reconciliation Amendment Modification Waiver Clause Revenue Increase Attribution Disclosure Corporate Authority Representation Arbitrator Selection Procedure Patent Family Portfolio Disclosure Share Withholding Tax Settlement Liquidity Position Snapshot Disclosed

Administrative Efficiency Net Loss Reported Burn Rate Controlled Priority Review Or Pdufa Disclosed Mrna Drug Platform Interim Data Positive Checkpoint Inhibitor Program Kol Endorsement Personnel Cost Decrease Disclosure

Combination Therapy Mentioned Lead Asset Progress Near Term Regulatory Decision Clinical Trial Result Indication Expansion

Accelerated Approval